Strategic use of patent opposition safeguard to improve equitable access to innovative health technologies: A case study of CAR T-cell therapy Kymriah

References

• Ali, S., Kjeken, R., Niederlaender, C., Markey, G., Saunders, T. S., Opsata, M., Moltu, K., Bremnes, B., Grønevik, E., Muusse, M., & Håkonsen, G. D. (2020). The European medicines agency review of Kymriah (tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The Oncologist, 25(2), 321. doi: 10.1634/theoncologist.2019-0233
   Web of Science ®Google Scholar
• Bach, P. B., Giralt, S. A., & Saltz, L. B. (2017). FDA approval of tisagenlecleucel: Promise and complexities of a $475 000 cancer drug. The Journal of the American Medical Association, 318(19), 1861–1862. https://doi.org/10.1001/jama.2017.15218
   PubMed Web of Science ®Google Scholar
• Brigand, T., Prokupkova, A., & Muller, G. (2018). CAR-T Cell therapies: How much for survival? Association of European Cancer Leagues, 1–8.
   Google Scholar
• Cavallo, J. (2018). Weighing the cost and value of CAR T-cell therapy. The American Society of Clinical Oncology Post. https://ascopost.com/issues/may-25-2018/weighing-the-cost-and-value-of-car-t-cell-therapy/
   Google Scholar
• Charles, N. (2019a). Oppositions to the grant of European Parent No. 3214091/17153799.6 in the name of: The Trustees of the University of Pennsylvania.
   Google Scholar
• Charles, N. (2019b). European Patent Application No. 17191702.4 in the name of: The Trustees of the University of Pennsylvania.
   Google Scholar
• CMS. (2017). Innovative treatments call for innovative payment models and arrangements. Press Release CMS.
   Google Scholar
• Correa, C. M. (2007). Guidelines for the examination of pharmaceutical patents: developing a public health perspective. Châtelaine: ICTSD.
   Google Scholar
• Douglass, C. H., Pedrana, A., Lazarus, J. V., FM‘t Hoen, E., Hammad, R., Leite, R. B., Hill, A., & Hellard, M. (2018). Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Medicine, 16(1), 1–9. https://doi.org/10.1186/s12916-018-1162-z
   Google Scholar
• Durisch, P. (2019). Novartis drops the Kymriah patent that was opposed by Public Eye. Public Eye Press Release.
   Google Scholar
• European Patent Office, European Patent Convention. (1973). https://www.epo.org/law-practice/legal-texts/html/epc/1973/e/contents.html
   Google Scholar
• European Patent Office. (2013). EPO Revokes Patent in the Brüstle Case. European Patent Office.
   Google Scholar
• Gaessler, F., Harhoff, D., & Sorg, S. (2017, October 30). Patents and cumulative innovation–evidence from post-grant patent oppositions. Academy of Management proceedings. https://doi.org/10.5465/AMBPP.2017.302
   Google Scholar
• Gil Abinader, L., & Contreras, J. L. (2019). The Patentability of Genetic Therapies: CAR-T and Medical Treatment Exclusions Around the World.
   Google Scholar
• Grupp, S. (2019). Cell therapy for leukaemia: Development and current status of Kymriah. Human Gene Therapy, 30(8), A8–A9.
   Web of Science ®Google Scholar
• Gugliuzza, P. R. (2017). Quick decisions in patent Cases. Georgetown Law Journal, 106, 619.
   Web of Science ®Google Scholar
• Herper, M. (2017). Novartis CEO's Dilemma: Is $475,000 Too much for A leukemia breakthrough? Or Is It Not Enough? Forbes. https://www.forbes.com/sites/matthewherper/2017/08/30/novartis-ceos-dilemma-is-475000-too-much-for-a-leukemia-breakthrough-or-is-it-not-enough/
   Google Scholar
• Hollywood, J., & Denney, F. (2019). The rise of patent wars in Europe’s gene therapy space. Your World First.
   Google Scholar
• Homer, C. (2018). UK panel rejects Kymriah for adults with lymphoma due to cost. HemOnc Today.
   Google Scholar
• Huettermann, Michalski and Partner Patent Attorneys. (2017). Double win for Kymriah CAR-T. The Rhineland Biopatent Gazette.
   Google Scholar
• ICER, Institute for Clinical and Economic Review. (2018). Positive ICER report for Kymriah and Yescarta. PharmacoEconomics & Outcomes News.
   Google Scholar
• Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., Chabannon, C., Perales, M. A., Hudecek, M., Aljurf, M., Andritsos, L., Barrett, J. A., Bachanova, V., Bonini, C., Ghobadi, A., … Hashmi, S. K. (2019). Clinical utilization of chimeric antigen receptor T cells in B cell acute Lymphoblastic Leukemia: An expert opinion from the European society for blood and marrow transplantation and the American society for transplantation and cellular therapy. Biology of Blood and Marrow Transplantation, 25(3), e76–e85. http://doi.org/10.1016/j.bbmt.2018.12.068
   PubMedGoogle Scholar
• Kimani, J., Adhiambo, J., Kasiba, R., Mwangi, P., Were, V., Mathenge, J., Macharia, P., Cholette, F., Moore, S., Shaw, S., & Becker, M. (2020). The effects of COVID-19 on the health and socio-economic security of sex workers in Nairobi, Kenya: Emerging intersections with HIV. Global Public Health, 1–10.
   Web of Science ®Google Scholar
• Lancet, T. (2017). CAR T-cells: An exciting frontier in cancer therapy. The Lancet, 390, 1006. https://doi.org/10.1016/S0140-6736
   Web of Science ®Google Scholar
• Liu, J., & Holle, L. M. (2017). Tisagenlecleucel (Kymriah) for acute lymphoblastic leukemia. New Drug Review.
   Google Scholar
• Manu, T. (2017). Challenging the validity of patents: Stepping in line with EPO and US Jurisprudence. IIC-International Review of Intellectual Property and Competition Law, 48(7), 813–837. doi: 10.1007/s40319-017-0633-7
   Web of Science ®Google Scholar
• Medecins Du Monde. (2019). Press Kit: Opposition against the European patent Covering Kymriah.
   Google Scholar
• Medline. (2017). The key to unlocking CARs. Nature Biotechnology, 35(10).
   Web of Science ®Google Scholar
• Mullin, E. (2017). Kymriah gene therapy for cancer. MIT Technology Review, 120(6), 18.
   Google Scholar
• National Institute for Health and Care Excellence. (2019). NICE recommends Kymriah for diffuse large B-cell lymphoma. Pharmaco Economics & Outcomes News.
   Google Scholar
• Phrmaletter, T. (2018). Kymriah cost dispute goes to heart of pharma's pricing row. The Phrmaletter. https://www.thepharmaletter.com/article/novartis-overpricing-kymriah-by-nearly-200-says-journal-report
   Google Scholar
• Plomer, A. (2015). Patents, human rights and access to science. Edward Elgar Publishing.
   Google Scholar
• A Public Eye Report. (2018). Protect patients, not patents. A Public Eye Report.
   Google Scholar
• Robinson, J. C., Howell, S., & Pearson, S. D. (2018). Value-Based pricing and patient access for Specialty drugs. American Medical Association, 319(21), 2169–2170. https://doi.org/10.1001/jama.2018.5367
   PubMed Web of Science ®Google Scholar
• Shapiro, M. (2019). A new therapy has been putting previously untreatable cancers into remission. CTV News.
   Google Scholar
• Shi, Q. (2003). Reexamination, opposition, or litigation-Legislative efforts to Create a post-grant patent quality Control system. AIPLA Quarterly Journal, 31, 433–434.
   Google Scholar
• Singhroy, D. (2017). The public sector role in funding CAR T technologies. Knowledge Ecology International. https://www.keionline.org/sites/default/files/CAR-T_Singhroy.pdf
   Google Scholar
• Upton, J. (2018). Kymriah and Yescarta Leading the CAR-T Race. Pharmaceutical Executive.
   Google Scholar
• U.S. Food and Drug Association. (2017). BL 125646/0, Biologics License Application Approval Letter for Novartis Pharmaceuticals.
   Google Scholar
• Vawda, Y. A. (2014). After the Novartis Judgment - Evergreening Will Never be the Same Again! 18 Law Democracy and Development 307.
   Google Scholar
• World Health Organization. (2006). Public health innovation and intellectual property rights.
   Google Scholar
• World Trade Organization, The Agreement on Trade-Related Aspects of Intellectual Property Rights. (1995). https://www.wipo.int/export/sites/www/treaties/en/agreement/pdf/trips.pdf
   Google Scholar